Abiomed’s Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk
Summary: Abiomed is a company with a superb product in the mid-market space while what appears on the surface is an...
Month: January 2022
360 DigiTech: Cheap Shares And Now A 5.6% Dividend Yield To Boot
Summary: The company keeps on growing and shifting its business model to platform services where it doesn't incur credit...
Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Summary: Absci, a Vancouver-based drug discovery company that IPOd in July last year, has seen its market cap fall from...